A detailed history of Pdt Partners, LLC transactions in Evolus, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 64,741 shares of EOLS stock, worth $702,439. This represents 0.09% of its overall portfolio holdings.

Number of Shares
64,741
Previous 64,334 0.63%
Holding current value
$702,439
Previous $677,000 33.83%
% of portfolio
0.09%
Previous 0.08%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$9.99 - $14.91 $4,065 - $6,068
407 Added 0.63%
64,741 $906,000
Q2 2023

Aug 14, 2023

BUY
$7.23 - $10.52 $205,368 - $298,820
28,405 Added 79.06%
64,334 $467,000
Q1 2023

May 15, 2023

BUY
$7.81 - $11.05 $280,605 - $397,015
35,929 New
35,929 $303,000
Q1 2021

May 17, 2021

SELL
$3.2 - $16.51 $62,688 - $323,430
-19,590 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$3.03 - $5.48 $224 - $405
-74 Reduced 0.38%
19,590 $77,000
Q2 2020

Aug 14, 2020

BUY
$3.53 - $6.17 $69,413 - $121,326
19,664 New
19,664 $104,000

Others Institutions Holding EOLS

About Evolus, Inc.


  • Ticker EOLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 56,094,800
  • Market Cap $609M
  • Description
  • Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...
More about EOLS
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.